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Abstract
Introduction: Therapy-related acute myeloid leukemia (t-AML) remains a late consequence of exposure to cytotoxic 
chemo- and/or radiotherapy for prior malignant or non-malignant disorders. The prognosis of t-AML is extremely poor, 
and allogeneic stem cell transplantation (allo-SCT) seems to be the most effective therapeutic approach.We evaluated 
the efficacy and safety of allo-SCT for t-AML preceded by solid tumors and lymphomas.
Material and methods: Study patients were retrospectively identified using our institutional database. Nineteen patients 
(12 female, 7 male), median age 53 years, underwent allo-SCT for t-AML between 2006 and 2018.
Results: Prior malignancy was diagnosed at median age of 43.9 years. Among 19 patients included in the study, 6 (32%)  
had prior breast cancer, 2 (11%) were diagnosed with papillary thyroid cancer, and 2 (11%) were treated for lymphoma. 
A variety of other cancers were diagnosed in the remaining 9 patients. Median time from previous malignancy to devel-
opment of t-AML was 4.9 years. Fourteen patients (74%) were transplanted in first complete remission (CR1), 4 patients 
(21%) were in CR2, and 1 patient received graft being in active disease. 10 patients (53%) are alive at last contact in 
CR. Patients died mainly from infectious complications. Median follow-up from prior malignancy and from transplanta-
tion was 9.5 years and 1.82 years, respectively. The 2-year overall survival (OS) was 57%. Median OS for survivors is  
4.08 years. Grafts from unrelated donors and the presence of acute graft-versus-host disease affected OS.
Conclusions: Allo-SCT remains an effective therapy for t-AML.
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Introduction
Therapy-related acute myeloid leukemia (t-AML) is a rare 
condition that accounts for 1–7% of all AML cases [1, 2]. 
It arises as a devastating consequence of prior exposure 
to radio- or chemotherapy for various solid cancers and/ 
/or hematologic malignant and non-malignant disorders. 
Direct genotoxic damage by prior radiation and chemothe-
rapeutics, as well as the presence of a pre-existing clonal 
population that remained chemo-resistant, are postulated 
mechanisms responsible for the development of a new ma-
lignancy [3, 4]. It is estimated that adult patients after on-
cological treatment have an approximately quadrupled risk 
of developing AML compared to the general population [1]. 
Acta Haematologica Polonica 2021, vol. 52, no. 2
www.journals.viamedica.pl/acta_haematologica_polonica104
One may speculate that the incidence of t-AML is escalating 
along with the increasing cure rate of solid tumors and 
lymphomas [5].
According to the 2017 European LeukemiaNet (ELN) re-
commendations, t-AML should be categorized as a high-risk 
disease due to its often adverse cytogenetic profile [6]. It is 
estimated that approximately 50% of patients with t-AML 
present unfavorable cytogenetic abnormalities including 
deletions in chromosomes 5, 7 and 17, complex karyotype 
or translocations involving chromosome 11q23. All these 
are known to be associated with poor responses to thera-
py and shorter overall survival [7–9].
Other negative factors predisposing to the development 
of t-AML include: older age at diagnosis, frequent comorbidi-
ties (especially cardiac, renal and liver disfunction), type of 
prior malignancy, and exposure to specific cytotoxic drugs. 
Patients with t-AML are usually aged 40–66 [10]. The most 
common prior malignancy is breast cancer: up to 40% of 
cases in some published studies [7, 11, 12]. Among cyto-
static agents, prior treatment with alkylating agents and 
topoisomerase II inhibitors (e.g. etoposide, anthracyclines) 
is considered to be the most leukemogenic [13]. All the-
se factors may affect the disease outcome and make this 
patient population of great interest. Despite several novel 
agents that can be attempted in the treatment of high-risk 
AML (e.g. midostaurin, venetoclax), allogeneic stem cell 
transplantation (allo-SCT) still remains the only curative 
therapeutic approach.
Here, we present our retrospective data on 19 patients 
with t-AML who underwent allo-SCT.
Material and methods
Study patients were retrospectively identified through 
the use of our institutional database of medical records. 
Therapy-related AML was defined as AML arising at any 
time after exposure to chemo- and/or radiation therapy 
for previous solid tumor or lymphoma [9]. Oncological tre-
atment before developing t-AML was considered intense if 
patients received chemotherapy as well as radiation and 
non-chemotherapy agents (e.g. monoclonal antibodies, 
hormonotherapy), moderate if they received chemotherapy 
and radiation, and mild if they were treated surgically with 
subsequent radiation [7].
The diagnosis of t-AML, genetic risk stratification and 
response criteria to therapy were based on the ELN recom-
mendations [6].
Patients were treated according to the Polish Adult 
Leukemia Group (PALG) protocol with standard induction 
chemotherapy including DA ±C regimen (daunorubicin, cy-
tarabine, cladribine). One patient received induction con-
sisting of daunorubicin and etoposide. For those who achie-
ved complete remission (CR), consolidative chemotherapy 
consisting of high-dose cytarabine was administered. For 
patients who did not respond to induction or who relapsed 
after achieving CR1, the following salvage regimens were 
given: CLAM (cladribine, cytarabine, mitoxantrone), DAC, DA 
and MEC (mitoxantrone, etoposide, cytarabine).
Response to treatment was assessed after each cycle 
of chemotherapy as well as before transplantation and at 
days +30, +60, +100, and then every 2–6 months after the 
procedure. The response was assessed using cyto-morp-
hological evaluation of bone marrow and measurement of 
minimal residual disease (MRD) by flow cytometry. Addi-
tionally, donor chimerism was assessed by short tandem 
repeat polymerase chain reaction.
Acute and chronic graft-versus-host disease (GvHD) 
were graded according to the standard criteria [14, 15].
Not all data was available due to the retrospective na-
ture of the study. All patients provided informed consent 
in accordance with the Declaration of Helsinki.
Statistics
Time to event was assessed from the day of transplanta-
tion. Nonparametric comparisons of group means were 
performed using the Mann-Whitney U test. Proportions 
were compared by Fisher exact test. The Kruskal-Wallis 
test was used to compare more than two independent 
groups of variables.
Overall survival (OS) was defined as time from day of 
transplant to death from any cause. The distribution for OS 
was estimated using Kaplan and Meier method and com-
pared using the log-rank test. A p <0.1 was considered sig-
nificant. Proportional hazard models (Cox regression) were 
fitted to investigate effects of prognostic factors for OS. All 
computations were performed with StatSoft Poland analy-
sis software (version 12.0).
Results
Patient characteristics
Nineteen patients (12 female, 7 male) with t-AML with 
a median age of 54 at diagnosis (range 18–70) underwent 
allo-SCT between 2006 and 2018.
Prior malignancy had been diagnosed at a median age 
of 43.9 (range 12.9–70.3). Of the 19 patients included in 
the study, 6 (32%) had a prior diagnosis of breast cancer, 
2 (11%) were previously diagnosed with papillary thyroid 
cancer, and 2 (11%) were treated for lymphoma (1 patient 
with Hodgkin’s disease and 1 with ocular B-cell lymphoma). 
Different solid cancers were diagnosed in the remaining 
9 patients. All the patients were in complete remission (CR) 
after oncological treatment.
Median time from previous malignancy to development 
of t-AML was 4.9 years (range 0.93–17.56). Three patients 
had prior myelodysplastic syndrome. According to the ELN 
2017, 6 patients were in the adverse risk category, 10 in 
the intermediate, and 3 in the favorable [6].
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Induction regimen consisted of DAC (n =10), DA (n =8) 
or daunorubicin with etoposide (n =1). Sixteen patients 
(84%) achieved first CR, however 3 of them relapsed af-
ter consolidation and proceeded to salvage chemotherapy. 
Three patients remained resistant to induction treatment 
and required re-induction. In total, 14 patients (74%) had 
CR1 at transplant, 4 patients (21%) were in CR2, and 1 pa-
tient was transplanted in active disease. Minimal residual 
disease was negative in 9 patients (38%) before procedu-
re and positive in 2 (11%). In 8 patients (43%), the results 
were missing or there was no immunophenotype to follow. 
Patient characteristics are set out in Table I.
Transplant data
Baseline characteristics  
of transplanted patients
Median recipient age was 53 (range 18–70). Median time 
from diagnosis of t-AML to transplantation was 7.1 months 
(range 4.9–20.5). Six patients were transplanted from 
an HLA-matched sibling and 13 patients received either 
10/10 HLA-matched unrelated donor (n =11) or 9/10 HLA- 
-mismatched grafts (n =2). Peripheral blood was a source 
of stem cell for 18 patients and one patient received stem 
cells from bone marrow. In total, myeloablative conditio-
ning (MAC) was used in eight patients, whereas reduced 
intensity conditioning (RIC) was provided for 11 subjects. 
MAC consisted of busulfan and cyclophosphamide (BuCy) 
and fludarabine-based regimens were given as RIC. GvHD 
prophylaxis included cyclosporine (n =15), cyclosporine 
with mycophenolate mofetil (n =3), or mycophenolate 
mofetil alone (n =1).
Outcomes of transplanted patients
There were no primary graft failures (PGF). Median time to 
engraftment was 18 days (range 12–26).
Acute and chronic GvHD developed in seven (37%) and 
two (11%) patients, respectively. Acute GvHD grade III/IV 
occurred in one patient. One patient presented mild and 
one severe chronic GvHD [15].
Two patients developed life-threatening Enterococci 
bacteremias (E. cloacae and faecium) in early post-trans-
plant period. One patient developed veno-occlusive disease 
(VOD). The other complications were mild and included mu-
cositis (n =7), diarrhea (n =2) and fever (n =2).
None of the patients died within 30 days of transplan-
tation, whereas one patient died before day +100 due to 
septic shock associated with E. cloacae. Post transplanta-
tion CR rate was achieved in 18 patients (95%). One pa-
tient relapsed 14 months after transplantation and finally 
died having failed to respond to salvage chemotherapy.
In total, nine (47%) patients have died. The main cau-
ses of death included pulmonary aspergillosis (n =2), re-
currence of primary malignancy (n =2), ovarian and lung 
cancer fungal neuroinfection (n =1), AML relapse (n =1) 
Table I. Patient characteristics
Variable n =19
Gender (female/male) 12/7





























Treatment of primary malignancy







Hemoglobin level [g/dL]; median (range) 9.3 (6.9–12.8)
Leukocyte count [×109/L]; median (range) 5.2 (1.14-45.8)
Platelet count [×109/L]; median (range) 49.5 (8–182)
Blasts in blood [%]; median (range) 9.5 (0–94)
Blasts in bone marrow (%); median (range) 57.5 (20–94)







Prior MDS, n [%] 3 (15)














Time from t-AML to transplant, months; me-
dian (range)
7.1 (4.9–20.5)
ELN — European LeukemiaNet; MDS — myelodysplastic syndrome; CR1 — first complete remis-
sion; CR2 — second complete remission; MRD — minimal residual disease; t-AML — therapy-
-related acute myeloid leukemia
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and septic shock (n =1). Cause of death remains unknown 
in two patients.
Ten patients (53%) are alive at last contact and all rema-
in in CR with full donor chimerism. Median follow-up from 
diagnosis of prior malignancy, t-AML and transplantation 
are 9.5 years, 2.36 years, and 1.82 years, respectively. 
Table II. Transplant data
Variable n =19
Age of recipient, median; years (range) 53 (19–71)
Age of donor, median; years (range) 34 (19–68)




















Number of transplanted CD34-positive 
cells [×106/kg]; median (range)
5.34 (2.7–9.67)
ANC >0.5 [×109/L]; median (range) 18 (12–26)
PLT >20 [×109/L]; median (range) 13 (7–25)












Chronic GvHD, n [%] 2 (11)
Hematologic relapse, n [%] 1 (5)
Death before day +100, n [%] 1 (5)
Alive at last contact, n [%] 10 (53)




Median follow-up from t-AML diagnosis, 
years; median (range)
2.36 (0.8–13.9)
Median follow up from prior malignancy, 
years; median (range)
9.5 (2.56–20.8)
HLA — human leukocyte antigens; ANC — absolute neutrophil count; PLT — platelets; GvHD — graft-
-versus-host disease; CsA — cyclosporin A; MMF — mycophenolate mofetil; t-AML — therapy-related 
acute myeloid leukemia
Transplant data is summarized in Table II. The 2-year OS 
was 57% (Figure 1). Median OS for survivors is 4.08 years 
(range 1.54–13.3).
Type of donor and presence of acute GvHD had stati-
stically significant impacts on overall survival. Graft from 
unrelated donor was associated with a better outcome 
[hazard ratio (HR) 3.85, 95% confidence interval (CI): 0.97– 
–15.2, p <0.1]. Presence of acute GvHD (aGvHD) negative-
ly affected OS [HR 3.73, 95%CI: 0.9–15.3, p <0.1]. Details 
are shown in Table III.
Discussion
Therapy related-AML can refer to any leukemic process re-
sulting from previous exposure to leukemogenic chemothe-
rapeutic agents, and this term can be used interchangeably 
with secondary AML (sAML) [4, 16].
The pathophysiology of t-AML is very heterogenous. 
It has been proved that cytostatics have a direct mutagenic 
Figure 1. Overall survival (OS) for therapy-related acute myeloid 
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OS at 2 years =57%
Table III. Univariate and multivariate analysis of risk factors for 
overall survival
Univariate analysis (log rank) Multivariate analysis 
(Cox regression)
Risk factor OS at 2 
years



















OS — overall survival; HR — hazard ratio; CI — confidence interval; GvHD — graft-versus-host 
disease
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impact on DNA, resulting in single- and double-strand 
breaks in repair processes and chromosomal breakage 
[17]. Among them, the role of alkylating agents and to-
poisomerase II inhibitors is well documented. Of note is 
that these drugs are widely used in the therapy of breast 
cancer, so it is unsurprising that this neoplasm was the 
commonest in our cohort, accounting for 32% of included 
patients [11, 17].
It has also been speculated that hematopoietic malig-
nant clones can be already present at the time of cancer 
development, and reach their potential to transform into 
myeloid neoplasms after cytotoxic exposure [4].
It is still unclear whether the well-known poor outcome 
of t-AML is a result of previous malignancy, or can be expla-
ined by other factors such as unfavorable genetic profile or 
older age. Approximately 50% of patients with t-AML were 
found to have adverse karyotype abnormalities in a Danish 
study, but the long-term outcome remained independent 
of cytogenetics [2].
Interestingly, patients with core binding factor (CBF) 
factor t-AML were found to have a worse prognosis than 
those with de novo AML [18]. The European Bone Marrow 
Transplantation (EBMT) Group compared the post-trans-
plant outcomes of patients with de novo AML to those 
transplanted for t-AML. In multivariate analysis, patients 
with t-AML had lower OS, lower leukemia-free survival (LFS), 
lower relapse-free survival (RFS), and higher non-relapse 
mortality (NRM) compared to newly diagnosed AML. There 
was no difference between the compared groups when de 
novo AML patients were transplanted in active disease, and 
the latter remained an independent risk factor for outco-
me after allo-SCT [19].
A large cohort study reported by the Center for Inter-
national Bone Marrow Transplant Research (CIBMTR) ana-
lyzed 545 patients with t-AML who underwent allo-SCT in 
order to identify risk factors that negatively affected outco-
me [20]. The study patients received prior chemotherapy or 
radiation for solid tumors or hematological malignancies. 
Median age of the studied population was 40. Nearly half 
of the patients had a prior history of lymphoma and 16% 
had breast cancer. Only 30% of individuals had adverse 
cytogenetics. OS at 5 years was highly unsatisfactory at 
only 22% (nota bene: 57% at 2 years in our study). The 
following factors had an impact on OS: age >35 years, ad-
verse cytogenetic profile, no remission at transplant, and 
graft from an unrelated donor. For patients without any 
of these factors, 5-year OS reached 50%. In contrast, OS 
was 4% in patients presenting all of the abovementioned 
factors. The incidence of aGvHD was comparable with our 
study: 39% versus 37%.
We have proved that OS is negatively affected by the oc-
currence of aGvHD and grafts from related donors. Disease 
status at transplantation and type of conditioning did not in-
fluence OS in our study. The impact of preparative regimen 
on the results of transplantation for t-AML with antecedent 
lymphoma was examined in a study by the EBMT Group. It 
was demonstrated that patients receiving RIC had a lower 
risk of NRM and improved LFS compared to those after 
MAC. OS at 2 years for the entire cohort was 37.4%. Moreo-
ver, patients transplanted in active disease, at older age, 
with adverse cytogenetics and prior autologous stem cell 
transplantation (auto-SCT) displayed worse outcomes [21]. 
If we consider the results of allo-SCT for patients with t-AML 
preceded by hematological neoplasms and solid tumors, 
OS and LFS at year 2 were 44.5% and 38.8% respectively. 
Patients receiving MAC regimen had decreased relapse 
rate, but higher NRM. No differences in terms of OS, LFS 
and RFS were demonstrated [22].
Another study reported on 65 patients with t-AML/ 
/MDS following allo-SCT [7]. Median follow-up for survivors 
was 72 months. OS at 2 years was noticeably lower than 
in our study (34% vs. 57%), however the study population 
was slightly different. AML relapse accounted for 41% of 
deaths, and this finding was in contrast with our observa-
tions, where there was only one fatal relapse among nine 
deceased patients. On the contrary, our patients died mai-
nly from infectious complications. Unexpectedly, we noticed 
significantly better OS after transplantation from an unrela-
ted donor. This latter finding is difficult to explain, although 
the study group was small. The EBMT Group demonstrated 
lower risk of relapse but higher NRM in patients transplan-
ted from unrelated donors [23].
We demonstrated that the occurrence of acute GVHD 
negatively influenced survival (28% vs. 57% at 2 years), 
and this finding is with line with data presented by the 
EBMT Group [23].
The leukemogenic role of conditioning regimens used 
before auto-SCT for lymphoma has also been highlighted by 
others [24]: it was demonstrated that therapy with alkyla-
ting agents and total-body irradiation (TBI) in doses higher 
than 12 Grey (Gy) increases the risk of t-AML development. 
Cyclophosphamide-based regimens are proven to be less 
leukemogenic.
Regarding the lymphoma cases from our study, the 
outcome was as follows: one patient was primarily diagno-
sed with ocular B-cell lymphoma at the age of 12. He was 
successfully treated with a combination of chemo- and ra-
diotherapy, and t-AML occurred six years later. He is alive 
13 years after allo-SCT, being in CR. A second patient de-
veloped t-AML 17 years after therapy for Hodgkin’s lymph-
oma. Due to his prior malignancy he received three lines 
of chemotherapy (ABVD — adriamycin, bleomycin, vinblast-
ine, dacarbazine; BEACOPP — bleomycin, etoposide, doxo-
rubicin, cyclophosphamide, vincristine, procarbazine, and 
prednisone; and MOPP — mechlorethamine, vincristine, 
procarbazine, and prednisone) with subsequent radiothe-
rapy. He relapsed within 14 months after allo-SCT and died 
of resistant leukemia.
Acta Haematologica Polonica 2021, vol. 52, no. 2
www.journals.viamedica.pl/acta_haematologica_polonica108
An interesting dilemma is whether a patient with t-AML 
should be proceeded to auto-SCT. Surprisingly, 3-year OS 
was comparable between patients who received auto- 
and allo-SCT. Transplant-related mortality was only 12%, 
although the relapse incidence was 83% for patients not 
transplanted in CR. It has been suggested that only young 
patients transplanted in complete remission may benefit 
from this procedure [25].
However, it should be remembered that according to 
the current EBMT recommendations, auto-SCT cannot be 
considered as a standard of care in this indication, even 
in children [26]. This can be performed only within clinical 
trials for individual patients after careful assessment of 
the potential risks and benefits.
Conclusions
Despite the low number of included patients and the 
relatively short follow-up, our study has confirmed an 
unexpectedly high efficacy of allo-SCT for poor-prognosis 
patients with t-AML.
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